Meetings - The ASCO Post

For the treatment of advanced melanoma that is refractory to anti–PD-1 antibodies, there is no standard approach. The various options, with a look to the future, were discussed by Melinda L. Yushak, M...

Lung Cancer

By Caroline Helwick / October 25, 2023 / 2023 Debates and Didactics in Hematology and Oncology Conference

The New Era of Perioperative Therapy in Non–Small Cell Lung Cancer

Recent developments in surgery and therapeutics are changing the perioperative approach to non–small cell lung cancer (NSCLC). These advances were discussed at the 2023 Debates and Didactics in Hemato...

Lymphoma

By Caroline Helwick / September 25, 2023 / 2023 Debates and Didactics in Hematology and Oncology Conference

Understanding the Treatment of Waldenström’s Macroglobulinemia

Waldenström’s macroglobulinemia is a rare and incurable low-grade B-cell lymphoproliferative disease defined by specific genotypic subtypes that have implications for treatment response and long-term ...

2023 Debates and Didactics in Hematology and Oncology Conference

Understanding the Treatment Options for PD-1–Refractory Melanoma

The New Era of Perioperative Therapy in Non–Small Cell Lung Cancer

Understanding the Treatment of Waldenström’s Macroglobulinemia

Risk of Gynecologic Cancers After 5 Years of Testosterone Use

Novel Prediction Model for Hearing Loss From Chemotherapy in Pediatric Patients With Cancer

Neoadjuvant Therapy for IBD-Related Rectal Cancer

Second-Line Endocrine Therapy With or Without Palbociclib Rechallenge in HR-Positive/HER2-Negative Advanced Breast Cancer

Retifanlimab-dlwr Approved for Anal Cancer